InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7.5% | 11.2% | 279.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 34.5% | 23.9% | 33.9% | 49.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -146.8% | -153.6% | -188.2% | -1,219% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -165.1% | -166.9% | -192.2% | -1,707.3% |
| EPS Diluted | -11.44 | -27.55 | -86 | -21,350.51 |
| % Growth | 58.5% | 68% | 99.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |